Grayscale Investments just announced a new fund offering access to a HOT new DeFi coin… And thanks to this newly established trust, I believe this coin could skyrocket up to 150x+ in the next 30 days alone! I've compiled everything you need to know about this once-in-a-lifetime DeFi project into a brand-new comprehensive guide…

You can get access to the report by clicking here now…

ADCT Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 4.10%

Insider Buying (Last 12 Months): $1,428,000.00

Insider Selling (Last 12 Months): $205,889.07

ADC Therapeutics Insider Trading History Chart

ADC Therapeutics Share Price & Price History

^$1.96

▼ -0.16 (-7.55%)

As of 12/20/2024 06:31 PM ET

Days: 30 | 90 | 365

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minutes of stepping into the Oval Office...

I put all the details together for you here — but please hurry.

ADC Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/11/2024	Redmile Group, Llc	Major Shareholder	Buy	100,000	$3.04	$304,000.00	13,145,712
12/4/2024	Redmile Group, Llc	Major Shareholder	Sell	25,352	$2.07	$52,478.64	15,566,731
7/1/2024	Redmile Group, Llc	Major Shareholder	Buy	400,000	$2.81	$1,124,000.00	12,995,040
6/17/2024	Robert Azelby	Director	Sell	6,995	$2.89	$20,215.55	53,005
5/7/2024	Ameet Mallik	CEO	Sell	29,731	$4.48	$133,194.88	1,167,348

$2 Trillion Disappears Because of Fed's Secretive New Move

From Stansberry Research | Ad

$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.

Click here to see his new research now.

SEC Filings (Institutional Ownership Changes) for ADC Therapeutics (NYSE:ADCT)

41.10% of ADC Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

ADC Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/25/2024	Wilmington Savings Fund Society FSB	100,000	$0.32M	0.0%	N/A	0.103%
11/19/2024	Barclays PLC	127,739	$0.40M	0.0%	+277.4%	0.132%
11/16/2024	Geode Capital Management LLC	953,171	$3M	0.0%	+15.6%	0.986%
11/15/2024	Barclays PLC	127,739	$0.40M	0.0%	+277.4%	0.132%
11/15/2024	XTX Topco Ltd	115,073	$0.36M	0.0%	+102.4%	0.119%
11/15/2024	Jane Street Group LLC	53,126	$0.17M	0.0%	+272.4%	0.055%
11/15/2024	Wellington Management Group LLP	168,557	$0.53M	0.0%	N/A	0.174%
11/15/2024	Sphera Funds Management LTD.	205,036	$0.65M	0.1%	-70.1%	0.212%
11/15/2024	State Street Corp	1,106,011	$3.48M	0.0%	+11.6%	1.144%
11/15/2024	Readystate Asset Management LP	17,039	$54K	0.0%	N/A	0.018%
11/15/2024	Redmile Group LLC	15,669,217	$49.36M	2.9%	+2.6%	16.206%
11/14/2024	MetLife Investment Management LLC	43,089	$0.14M	0.0%	+129.1%	0.045%
11/13/2024	FMR LLC	53,042	$0.17M	0.0%	N/A	0.055%
11/12/2024	Charles Schwab Investment Management Inc.	194,258	$0.61M	0.0%	+10.7%	0.201%
11/9/2024	Intech Investment Management LLC	12,998	$41K	0.0%	N/A	0.013%
10/3/2024	SG Americas Securities LLC	26,657	$84K	0.0%	N/A	0.032%
8/15/2024	Susquehanna Fundamental Investments LLC	10,355	$33K	0.0%	N/A	0.013%
8/15/2024	The Manufacturers Life Insurance Company	26,938	$85K	0.0%	N/A	0.033%
8/15/2024	Affinity Asset Advisors LLC	474,744	$1.50M	0.2%	N/A	0.574%
8/12/2024	XTX Topco Ltd	56,863	$0.18M	0.0%	+129.0%	0.069%
8/6/2024	Acadian Asset Management LLC	16,454	$51K	0.0%	N/A	0.020%
8/1/2024	Rhumbline Advisers	85,977	$0.27M	0.0%	N/A	0.104%
7/26/2024	Bank of New York Mellon Corp	205,221	$0.65M	0.0%	N/A	0.248%
7/22/2024	Sanibel Captiva Trust Company Inc.	113,000	$0.36M	0.0%	+9.7%	0.137%
5/21/2024	Sanibel Captiva Trust Company Inc.	103,000	$0.46M	0.0%	N/A	0.124%
5/16/2024	Redmile Group LLC	15,269,217	$68.56M	2.5%	-0.4%	18.446%
4/17/2024	Hennion & Walsh Asset Management Inc.	70,636	$0.32M	0.0%	+7.1%	0.086%
2/13/2024	Affinity Asset Advisors LLC	1,013,540	$1.68M	0.3%	-7.9%	0.000%
1/29/2024	Saxony Capital Management LLC	20,623	$34K	0.0%	N/A	0.000%
11/15/2023	Redmile Group LLC	14,178,045	$12.72M	0.6%	+0.9%	18.459%
11/15/2023	Affinity Asset Advisors LLC	1,100,000	$0.99M	0.3%	+83.3%	1.432%
11/13/2023	Acadian Asset Management LLC	156,048	$0.14M	0.0%	+613.8%	0.203%
8/14/2023	Prosight Management LP	5,583,900	$12.01M	3.7%	+71.4%	7.270%
8/11/2023	Vantage Consulting Group Inc	885,520	$1.90M	1.1%	-25.3%	1.153%
8/8/2023	AlphaCentric Advisors LLC	778,000	$1.67M	0.9%	+2.4%	1.013%
8/7/2023	Acadian Asset Management LLC	21,862	$45K	0.0%	N/A	0.028%
7/27/2023	Virtu Financial LLC	18,835	$40K	0.0%	N/A	0.025%
7/13/2023	Miracle Mile Advisors LLC	84,496	$0.18M	0.0%	N/A	0.110%
5/15/2023	Affinity Asset Advisors LLC	600,000	$1.17M	0.4%	N/A	0.781%
5/15/2023	GCM Grosvenor Holdings LLC	410,888	$0.80M	0.2%	-44.1%	0.535%
5/15/2023	Sio Capital Management LLC	2,160,632	$4.21M	2.1%	N/A	2.813%
5/12/2023	Prosight Management LP	3,257,360	$6.35M	3.0%	+603.1%	4.241%
5/12/2023	AlphaCentric Advisors LLC	760,000	$1.48M	1.0%	+155.5%	0.989%
5/10/2023	Pictet Asset Management SA	1,366,689	$2.67M	0.0%	+57.3%	1.779%
5/4/2023	Barclays PLC	334,272	$0.65M	0.0%	N/A	0.435%
2/15/2023	Nantahala Capital Management LLC	243,290	$0.93M	0.1%	N/A	0.317%
2/14/2023	Susquehanna International Group LLP	13,963	$54K	0.0%	-220.6%	0.018%
2/8/2023	Russell Investments Group Ltd.	17,800	$68K	0.0%	N/A	0.023%
2/7/2023	AlphaCentric Advisors LLC	297,500	$1.14M	1.1%	N/A	0.387%
1/20/2023	Values First Advisors Inc.	10,400	$40K	0.0%	N/A	0.014%
1/12/2023	Hennion & Walsh Asset Management Inc.	58,869	$0.23M	0.0%	+14.2%	0.077%
11/15/2022	Prosight Management LP	247,630	$1.19M	0.6%	N/A	0.322%
11/15/2022	Blue Owl Capital Holdings LP	733,568	$3.54M	1.5%	N/A	0.955%
11/14/2022	PDT Partners LLC	15,768	$76K	0.0%	N/A	0.021%
11/14/2022	Hennion & Walsh Asset Management Inc.	51,532	$0.25M	0.0%	+33.2%	0.067%
11/10/2022	ExodusPoint Capital Management LP	369,386	$1.78M	0.0%	+165.4%	0.481%
11/10/2022	Employees Retirement System of Texas	56,227	$0.27M	0.0%	-82.0%	0.073%
11/7/2022	TD Asset Management Inc.	74,690	$0.37M	0.0%	-19.1%	0.097%
9/23/2022	Capital Wealth Alliance LLC	35,000	$31K	0.0%	N/A	0.046%
8/19/2022	Walleye Capital LLC	888,700	$7.07M	0.2%	+257.8%	0.000%
8/13/2022	Vantage Consulting Group Inc	1,186,215	$9.43M	5.3%	-29.4%	0.000%
8/11/2022	Alps Advisors Inc.	45,563	$0.36M	0.0%	-42.2%	0.000%
8/11/2022	JPMorgan Chase & Co.	3,453,672	$27.46M	0.0%	+1.1%	0.000%
8/10/2022	Principal Financial Group Inc.	406,102	$3.23M	0.0%	+33.0%	0.589%
8/9/2022	Lazard Asset Management LLC	16,098	$0.13M	0.0%	N/A	0.000%
8/8/2022	Walleye Capital LLC	888,700	$7.07M	0.2%	+257.8%	1.290%
8/2/2022	Capital Wealth Alliance LLC	35,000	$31K	0.0%	N/A	0.000%
7/26/2022	Cypress Capital Group	10,000	$80K	0.0%	N/A	0.000%
7/19/2022	Hennion & Walsh Asset Management Inc.	38,700	$0.31M	0.0%	N/A	0.000%
5/27/2022	Walleye Capital LLC	248,354	$3.65M	0.1%	+446.1%	0.361%
5/16/2022	Matrix Capital Management Company LP	400,000	$5.88M	0.1%	N/A	0.581%
5/11/2022	JPMorgan Chase & Co.	3,414,630	$50.16M	0.0%	+6.9%	4.957%
5/9/2022	Principal Financial Group Inc.	305,246	$4.48M	0.0%	+0.7%	0.443%
5/4/2022	Prospera Financial Services Inc	5,921	$87K	0.0%	N/A	0.009%
3/3/2022	Walleye Capital LLC	45,478	$0.92M	0.0%	N/A	0.066%
2/14/2022	Redmile Group LLC	7,451,029	$150.51M	3.4%	-1.0%	10.816%
2/14/2022	Alliancebernstein L.P.	2,807,723	$56.72M	0.0%	+5.8%	4.076%
2/14/2022	Eventide Asset Management LLC	1,975,000	$39.90M	0.5%	+50.5%	2.867%
2/11/2022	Indie Asset Partners LLC	96,582	$1.95M	1.4%	-0.9%	0.140%
2/11/2022	Bioimpact Capital LLC	337,396	$6.82M	1.2%	-2.1%	0.490%
2/11/2022	Allianz Asset Management GmbH	58,030	$1.18M	0.0%	+20.5%	0.084%
2/10/2022	JPMorgan Chase & Co.	3,194,842	$64.54M	0.0%	-2.2%	4.637%
2/10/2022	Pictet Asset Management SA	1,300,803	$26.28M	0.0%	+17.0%	1.888%
2/9/2022	Principal Financial Group Inc.	303,234	$6.13M	0.0%	+3.9%	0.440%
2/9/2022	Lazard Asset Management LLC	1,863	$37K	0.0%	N/A	0.003%
2/9/2022	Alps Advisors Inc.	88,789	$1.79M	0.0%	-5.6%	0.129%
2/8/2022	Bank of America Corp DE	100,877	$2.04M	0.0%	+1,121.9%	0.146%
2/7/2022	American Century Companies Inc.	421,174	$8.51M	0.0%	+10.9%	0.611%
11/16/2021	Voloridge Investment Management LLC	30,847	$0.84M	0.0%	-60.8%	0.045%
11/16/2021	BioImpact Capital LLC	344,519	$9.36M	1.5%	+58.0%	0.500%
11/15/2021	Man Group plc	19,813	$0.54M	0.0%	N/A	0.029%
11/15/2021	Invesco Ltd.	223,598	$6.07M	0.0%	-0.9%	0.325%
11/15/2021	Virtus ETF Advisers LLC	19,728	$0.54M	0.2%	-8.4%	0.029%
11/15/2021	Dark Forest Capital Management LP	923	$25K	0.0%	N/A	0.001%
11/12/2021	CNA Financial Corp	14,805	$0.40M	0.1%	-13.0%	0.021%
11/12/2021	Magnetar Financial LLC	125,198	$3.40M	0.0%	-10.7%	0.182%
11/10/2021	Allianz Asset Management GmbH	48,170	$1.31M	0.0%	+134.8%	0.070%
11/10/2021	Alliancebernstein L.P.	2,654,217	$72.09M	0.0%	-13.1%	3.853%
11/9/2021	BlackRock Inc.	313,641	$8.52M	0.0%	+4.3%	0.455%
11/9/2021	Principal Financial Group Inc.	291,805	$7.93M	0.0%	-1.1%	0.424%

Data available starting January 2016

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Today's Range

Now: $1.96

$1.94

$2.18

50 Day Range

MA: $2.60

$1.89

$3.48

52 Week Range

Now: $1.96

$1.18

$6.04

Volume

1,895,521 shs

Average Volume

716,405 shs

Market Capitalization

$189.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.52

Who are the company insiders with the largest holdings of ADC Therapeutics?: ADC Therapeutics' top insider shareholders include:
Redmile Group, Llc (Major Shareholder)
Ameet Mallik (CEO)
Robert Azelby (Director)
Learn More about top insider investors at ADC Therapeutics.
Who are the major institutional investors of ADC Therapeutics?: ADC Therapeutics' top institutional investors include:
Redmile Group LLC — 16.21%
State Street Corp — 1.14%
Geode Capital Management LLC — 0.99%
Sphera Funds Management LTD. — 0.21%
Charles Schwab Investment Management Inc. — 0.20%
Wellington Management Group LLP — 0.17%
Learn More about top institutional investors of ADC Therapeutics stock.
Which institutional investors are selling ADC Therapeutics stock?: Within the last quarter, ADCT stock was sold by these institutional investors:
Sphera Funds Management LTD.
During the previous year, company insiders that have sold ADC Therapeutics company stock include:
Redmile Group, Llc (Major Shareholder)
Ameet Mallik (CEO)
Robert Azelby (Director)
Learn More investors selling ADC Therapeutics stock.
Which institutional investors are buying ADC Therapeutics stock?: During the last quarter, ADCT stock was acquired by institutional investors including:
Redmile Group LLC
Wellington Management Group LLP
Geode Capital Management LLC
State Street Corp
Wilmington Savings Fund Society FSB
Barclays PLC
Barclays PLC
XTX Topco Ltd

The #1 Coin for November 2024

From Crypto 101 Media | Ad